BioSpecifics Technologies Corp (BSTC) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its position in shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) by 7.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 265,676 shares of the biopharmaceutical company’s stock after buying an additional 18,562 shares during the period. Dimensional Fund Advisors LP owned about 3.70% of BioSpecifics Technologies Corp worth $13,154,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. AJO LP bought a new stake in shares of BioSpecifics Technologies Corp in the 2nd quarter worth approximately $501,000. Goldman Sachs Group Inc. lifted its holdings in shares of BioSpecifics Technologies Corp by 8.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 58,117 shares of the biopharmaceutical company’s stock worth $3,185,000 after purchasing an additional 4,297 shares during the last quarter. American International Group Inc. lifted its holdings in shares of BioSpecifics Technologies Corp by 7.1% in the 1st quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 222 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of BioSpecifics Technologies Corp by 35.5% in the 1st quarter. AQR Capital Management LLC now owns 74,159 shares of the biopharmaceutical company’s stock worth $4,064,000 after purchasing an additional 19,437 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in shares of BioSpecifics Technologies Corp by 16.9% in the 2nd quarter. New York State Common Retirement Fund now owns 18,519 shares of the biopharmaceutical company’s stock worth $917,000 after purchasing an additional 2,681 shares during the last quarter. 53.92% of the stock is currently owned by institutional investors.

Shares of BioSpecifics Technologies Corp (BSTC) opened at $44.17 on Tuesday. The stock has a market capitalization of $313.67, a P/E ratio of 27.44 and a beta of 1.64. BioSpecifics Technologies Corp has a 1-year low of $41.95 and a 1-year high of $58.79.

BioSpecifics Technologies Corp (NASDAQ:BSTC) last announced its earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.01. The firm had revenue of $6.52 million for the quarter, compared to the consensus estimate of $6.59 million. BioSpecifics Technologies Corp had a return on equity of 19.11% and a net margin of 42.40%. sell-side analysts anticipate that BioSpecifics Technologies Corp will post 1.59 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “BioSpecifics Technologies Corp (BSTC) Shares Bought by Dimensional Fund Advisors LP” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/14/biospecifics-technologies-corp-bstc-shares-bought-by-dimensional-fund-advisors-lp.html.

Several analysts recently issued reports on BSTC shares. HC Wainwright set a $72.00 price target on BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday, August 10th. BidaskClub downgraded BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. Finally, Zacks Investment Research downgraded BioSpecifics Technologies Corp from a “hold” rating to a “strong sell” rating in a report on Friday, August 11th.

BioSpecifics Technologies Corp Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply